AMDL, Inc., developer and marketer of tests for the early detection of cancer and other serious diseases, announced today it intends to gain significant market share in the rapidly expanding Chinese pharmaceutical market through recent licensing agreements and product acquisitions by its China subsidiary Jade Pharmaceutical from Chinese drug distributor and manufacturer JMB.

With the transfer of production licenses and manufacturing registration numbers, Jade Pharmaceutical will focus on selling into the China pharmaceutical products market with four new drugs (Marine and Sodium Chloride Injection, Lomefloxacin Aspartate Injection, Lysine Hydrochloride and Glucose Injection, Omeprazole Sodium for Injection) and two antibiotic medicines, Roxithromycin and Levofloxacin.

According to IMS Health, pharmaceutical product sales in China grew 20.4 percent to $11.7 billion in 2005, representing the third consecutive year the market has achieved more than 20 percent growth. China is projected to become the world's seventh largest pharmaceutical market by 2009. The market for antibiotic products (including Roxithromycin and Levofloxacin) exceeded (US) $4.8 billion globally in 2003 with a continuing estimated growth rate of 20 percent annually.

"The new licensing agreements and product acquisitions bolster Jade's existing pharmaceutical and consumer product offerings. We look forward to serving the rapidly expanding Chinese pharmaceutical market while continuing to develop and acquire compelling products," said Gary Dreher, AMDL CEO. Jade Pharmaceutical will manufacture products at the Jiangxi Jade Biochemistry Ltd. facility in the South China City of Shargro in the Jiangxi Province of China. At present, these products will only be sold in the People's Republic of China.

Source:佚名